Clinical response in advanced non-small cell lung cancer with high PD-L1 expression and MET exon 14 skipping mutation: a case analysis of overcoming immunotherapy resistance and literature review

In the precision management of non-small cell lung cancer (NSCLC), identifying driver mutations and evaluating immune-related biomarkers are essential. Yet, clear therapeutic protocols remain absent for tumors that concurrently carry MET exon 14 skipping mutations (METex14) and demonstrate elevated...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yefei Ruan, Lin Qiu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2026-05-01
Colecção:	Frontiers in Oncology
Assuntos:	MET14 exon skipping mutation non-small cell lung cancer programmed death-ligand 1 savolitinib tislelizumab
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1807242/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!